Meeting
2016 ASCO Annual Meeting
A first-in-human phase 1 study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma.
Authors
Patrick Y. Wen
Dana-Farber Cancer Institute, Boston, MA
Patrick Y. Wen , Timothy Francis Cloughesy , Alan Olivero , Xuyang Lu , Lars Mueller , Alexandre Fernandez Coimbra , Elizabeth Robins Gerstner , Jordi Rodon Ahnert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01547546
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2012)
DOI
10.1200/JCO.2016.34.15_suppl.2012
Abstract #
2012
Poster Bd #
201
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Escalation portion of phase II study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status.
First Author: Patrick Y. Wen
Poster
2015 ASCO Annual Meeting
A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.
First Author: Kathleen N. Moore
Poster
2012 ASCO Annual Meeting
A dose escalation, single arm, phase Ib-II combination study of BEZ235 with everolimus to determine the safety, pharmacodynamics and pharmacokinetics in subjects with advanced solid malignancies including glioblastoma multiforme.
First Author: Mohamad Adham Salkeni
Poster
2022 ASCO Annual Meeting
DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study.
First Author: David A. Reardon